Both the phase 1 and the phase 2 portions of the study will include induction therapy consisting of 1 year of therapy followed by maintenance therapy that will continue until progressive disease or unacceptable toxicity. Maintenance therapy will be IXAZOMIB alone on Days 1,4,8, & 11 of a 21-day cycle.